Skip to main content
Quest Diagnostics

COVID-19 and managing cardiovascular risk

Identify patients with higher cardiovascular risk due to COVID-19

The heart disease death rate in the US has been steadily declining over the long-term—but in 2020, it experienced the largest increase in at least two decades.1  Experts attribute this to deferred care and generally poorer health during the COVID-19 pandemic2, which is likely to impact cardiovascular health for many years to come.

COVID-19 can increase myocardial infarction and CVD mortality

Preexisting conditions like cardiovascular disease (CVD) make patients with COVID-19 particularly vulnerable to serious disease, complications, and death,3-5 but recent studies have shown that even patients without cardiac inflammation can be at increased risk for heart disease.6

Help prevent cardiovascular disease with enhanced diagnostic insights

The impact of COVID-19 on patients both with and without preexisting heart conditions makes it more vital than ever to monitor cardiovascular risk during SARS-CoV-2 (COVID-19) infection and recovery.

Quest Diagnostics empowers you and your patients with the testing insights you need to uncover hidden risk and identify disease in the earliest stages to help improve patient outcomes.

Patients most at risk for severe outcomes from COVID-19 or seasonal flu are those with underlying risk factors and conditions including:


Age 65 or older


History of elevated HbA1c (>6.5%)


Diagnosed cardiovascular disease


Diagnosed hypertension


Obesity (BMI ≥30)


History of elevated myeloperoxidase

(≥540 pmol/L within past 2 yrs)

Cardiometabolic testing

We offer a variety of testing approaches depending on individual patient needs. The test chart below lists some of the tests that can help you better understand your patients’ current health status:

Test name Test code CPT code
Lipid Panel, Standarda
Includes Cholesterol, Total (334), Triglycerides (896), HDL Cholesterol (608), LDL-Cholesterol (calculated), Cholesterol/HDL Ratio (calculated), Non-HDL Cholesterol (calculated)		 7600 80061
Cardio IQ® Lipoprotein Fractionation, Ion Mobility 91604 83704
Cardio IQ® Apolipoprotein B 91726 82172
Hemoglobin A1c 496 83036

Cardiovascular inflammation testing

Advanced biomarker testing can help you take action sooner
A biomarker assessment of risk-associated specific vascular inflammation markers can identify patients with vulnerable plaque who may benefit from preventive care and risk factor mitigation, as well as provide a clearer picture of your patients’ cardiovascular risk profile to inform better treatment decisions if they are exposed to a respiratory infection, such as SARS-CoV-2 (COVID-19) or seasonal influenza.

Test name Test code CPT code
Cardio IQ® Myeloperoxidase (MPO) 92814 83876
Cardio IQ® Lipoprotein Fractionation, Ion Mobility 94153 82542
Cardio IQ® Apolipoprotein B 94218 83698

References

  1. CDC. Provisional mortality data – United States, 2020. Posted March 31, 2021. Accessed October 28, 2021. https://www.cdc.gov/mmwr/volumes/70/wr/mm7014e1.htm
  2. Stobbe M. US deaths from heart disease and diabetes climbed amid COVID. Associated Press. June 9, 2021. Accessed June 10, 2021. https://apnews.com/article/coronavirus-pandemic-diabetes-science-heart-disease-health-213fe132f33c9428ea39274ffb96aa01
  3. CDC. Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19). Updated June 30, 2020. Accessed June 30, 2020. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html
  4. American College of Cardiology (ACC). ACC’s COVID-19 Hub. Accessed April 15, 2020. https://www.acc.org/latest-in-cardiology/features/ accs-coronavirus-disease-2019-covid-19-hub#sort=%40fcommonsortdate90022%20descending
  5. Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr. 2020;14(4):303-310. doi:10.1016/j.dsx.2020.04.004
  6. Katsoularis I, Fonseca-Rodríguez O, Farrington P, et al. Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study. Lancet 2021; 398(10300):599–607. doi:10.1016/S0140-6736(21)00896-5
  7. Puntmann VO, Carerj ML, Wieters I, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from Coronavirus Disease 2019 (COVID-19) JAMA Cardiol. 2020; 5(11):1265-1273. doi:10.1001/jamacardio.2020.3557

 

The CPT® codes provided are based on American Medical Association guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.
 

Test codes may vary by location. Please contact your local laboratory for more information.

During the COVID-19 health crisis, fast action and trusted information matter more than ever.

Find out what's happening

Learn More

Infectious Diseases

Resources

For your team: a treatment guide to lipid disorders

How to read your patient’s Cardio IQ® report

For patients: how Cardio IQ® makes a difference

For patients: contacting a 4myheart® expert

 

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.